Xconomy | Seattle - Business + Technology in the Exponential Economy

ZymoGenetics Gets $20M From Bristol

ZymoGenetics disclosed today that it has received a $20 million milestone payment from Bristol-Myers Squibb, as part of a larger partnership potentially worth $1.1 billion, which the companies announced in January. ZymoGenetics (NASDAQ: ZGEN) has now received $105 million under the deal, which gives Bristol-Myers Squibb the right to co-develop pegylated interferon lambda. It’s an experimental treatment for hepatitis C that is designed to kill the liver-damaging virus with fewer side effects than existing interferons.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: